RecruitingNot applicableNCT04065438
Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
Studying Idiopathic multidrug-resistant nephrotic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Kaneka Medical America LLC
- Intervention
- LIPOSORBER® LA-15(device)
- Enrollment
- 35 target
- Eligibility
- 75 years · All sexes
- Timeline
- 2020 – 2028
Study locations (10)
- Loma Linda University Children's Hospital, Loma Linda, California, United States
- Loma Linda University Hospital, Loma Linda, California, United States
- Nemours/Alfred I DuPont Hospital for Children, Wilmington, Delaware, United States
- Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
- Weill Cornell Medicine / NewYork-Presbyterian, New York, New York, United States
- University of North Carolina, Chapel Hill, North Carolina, United States
- Akron Children's Hospital, Akron, Ohio, United States
- Medical University of South Carolina Children's Hospital, Charleston, South Carolina, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- Children's Hospital of Richmond at VCU, Richmond, Virginia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04065438 on ClinicalTrials.govOther trials for Idiopathic multidrug-resistant nephrotic syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06664814An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental GlomerulosclerosisNational Human Genome Research Institute (NHGRI)
- RECRUITINGPHASE3NCT07220083A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)Boehringer Ingelheim
- RECRUITINGPHASE2NCT07268638A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)Akebia Therapeutics
- RECRUITINGPHASE2NCT06500702A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change DiseaseSanofi
- RECRUITINGPHASE1, PHASE2NCT06090227AMPK-activation by Metformin in FSGS: AMP-FSGSYale University
- RECRUITINGNCT05650619Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change DiseaseUniversity of Michigan
- ACTIVE NOT RECRUITINGPHASE3NCT03493685Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)Travere Therapeutics, Inc.
- RECRUITINGNANCT02235857Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in ChildrenKaneka Medical America LLC
See all trials for Idiopathic multidrug-resistant nephrotic syndrome →